Compare Synopsys, Inc. (SNPS) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Synopsys, Inc. vs Sanofi SA — how do they compare? Synopsys, Inc. trades at $388.58 (market cap $72.47B), while Sanofi SA trades at $44.05 (market cap $104.83B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays a 5.5% dividend while Synopsys, Inc. pays none. Which is the better fit depends on your goals.
| SNPS | SNY | |
|---|---|---|
Market Cap | $72.47B | $104.83B |
Sector | Technology | Health |
52-Week High | $645.59 | $52.34 |
52-Week Low | $378.46 | $41.33 |
Enterprise Value | $80.82B | $121.32B |
Dividend Yield | — | 5.5% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
